Immunology › Systemic Lupus Erythematosus

AI-Driven Benefit-Risk Analysis for Systemic Lupus Erythematosus

SLE benefit-risk analysis spans B-cell targeted biologics, type I interferon receptor antibodies, calcineurin inhibitors, and foundational antimalarials. ArcaScience delivers organ-specific safety profiling across belimumab, anifrolumab, voclosporin, and hydroxychloroquine—with integrated multi-organ flare and immunosuppressive risk modeling.

See Platform Request Demo

5,000,000+

Lupus patients globally

800+

SLE clinical trials analyzed

$3B

Global SLE therapeutics market

Limited

Approved therapies—high unmet need

Disease Overview

Why SLE Demands Specialized BRA

Systemic lupus erythematosus is a prototypical multi-organ autoimmune disease with unpredictable flare patterns, disproportionate impact on women of childbearing age, and a history of clinical trial failures. The limited approved therapy landscape, combined with severe organ manifestations in lupus nephritis and neuropsychiatric lupus, demands BRA frameworks that account for disease heterogeneity and cumulative immunosuppressive risk.

Serious Infection & Immunosuppression Risk

Belimumab, anifrolumab, and voclosporin all carry significant infection risks layered on top of background immunosuppression with mycophenolate and corticosteroids. BRA must model cumulative immunosuppressive burden, herpes zoster reactivation (particularly with anifrolumab), opportunistic infections, and the critical balance between disease control and infectious complications across organ-specific manifestations.

Hypersensitivity & Infusion Reactions

Belimumab carries risk of serious hypersensitivity reactions including anaphylaxis, with post-marketing reports of fatal outcomes. Infusion-related reactions require pre-medication protocols and long-term monitoring. BRA must account for the IV-to-SC formulation safety differences and the distinct reaction profiles in different ethnic populations, given lupus prevalence disparities.

Nephrotoxicity & Retinal Toxicity Monitoring

Voclosporin, as a calcineurin inhibitor for lupus nephritis, introduces nephrotoxicity risk in patients with already-compromised renal function. Hydroxychloroquine—the backbone of SLE treatment—requires long-term retinal toxicity monitoring with OCT screening, where cumulative dose-dependent maculopathy can cause irreversible vision loss. These require distinct longitudinal BRA modeling approaches.

Platform Capabilities

How ArcaScience Addresses SLE BRA

Our platform integrates SLE-specific multi-organ disease activity data, immunosuppressive safety models, and regulatory templates aligned with FDA and EMA lupus-specific guidance documents including the 2010 FDA SLE guidance and 2015 lupus nephritis guidance.

Data Intelligence

SLE Data Coverage

800+ SLE clinical trials including BLISS-52, BLISS-76, TULIP-1, TULIP-2, AURORA, and NOBILITY datasets. Adverse event data covering belimumab hypersensitivity, anifrolumab herpes zoster, voclosporin nephrotoxicity, HCQ retinal toxicity, and background immunosuppressant infection rates across all organ manifestations.

Explore Data Engine →

Decision Intelligence

Multi-Organ AI Models

AI models for cumulative immunosuppressive risk scoring, organ-specific flare prediction and safety impact modeling, herpes zoster reactivation risk stratification with anifrolumab, nephrotoxicity monitoring for voclosporin in lupus nephritis, and SRI-4/BICLA responder-safety correlation analysis. BRAT framework with SLE-specific regulatory precedent integration.

Explore AI Models →

Automated Outputs

SLE Regulatory Outputs

PSURs with infection safety deep-dives and organ-specific event tracking, RMPs with hypersensitivity monitoring and immunosuppression risk minimization, CTD Module 2.5 with SRI-4, BICLA, and renal response endpoint integration, and HEOR reports supporting the limited comparator landscape for HTA submissions.

Explore Outputs →

SLE Intelligence

Platform Performance in Lupus

3,200,000,000+

SLE adverse event data points

50%

Faster infection signal detection

Organ systems modeled

SLE regulatory submissions supported

Case Evidence — Systemic Lupus

Type I Interferon Receptor Antibody BRA for Multi-Organ Lupus

Challenge

A mid-size biotech required comprehensive benefit-risk assessment for their type I interferon receptor antibody across SLE patients with skin, joint, and renal manifestations, needing to demonstrate safety across organ subtypes while managing the herpes zoster signal that emerged during pivotal trials and early post-marketing experience.

Result

ArcaScience deployed organ-specific safety models that stratified herpes zoster risk by baseline immunosuppressive regimen, organ manifestation, and ethnicity. The platform identified that zoster risk was concentrated in patients on triple immunosuppression, enabling targeted risk minimization recommendations that supported a successful EMA RMP update and informed vaccination guidance in the product label.

2.8x

Faster zoster risk stratification

40%

More precise organ-specific safety profiling

View All Case Studies →

Lupus is inherently heterogeneous, and our safety data reflected that complexity. ArcaScience helped us untangle the herpes zoster signal from background immunosuppressive effects, which was exactly what EMA needed to see in our risk management plan. The organ-specific modeling capability was something we could not replicate internally.

Head of Immunology Safety

Mid-Size Biotech

Frequently Asked Questions

SLE Benefit-Risk Analysis

Our platform provides dedicated lupus nephritis BRA modeling that integrates data from AURORA (voclosporin), BLISS-LN (belimumab), and NOBILITY (obinutuzumab) trials. We model the complex interaction between nephritis-specific endpoints (complete renal response, proteinuria reduction) and safety concerns unique to renal patients, including voclosporin nephrotoxicity risk in patients with already-impaired GFR, infection risk stratification by eGFR category, and the benefit-risk of adding biologics to mycophenolate + corticosteroid background therapy.

Given that SLE disproportionately affects women of childbearing age, pregnancy safety is central to our BRA framework. We model teratogenicity risk for mycophenolate (Category D), the safety profile of hydroxychloroquine continuation during pregnancy (protective against neonatal lupus), belimumab pregnancy registry data, and the timing of treatment washout periods before conception. Our models also integrate antiphospholipid antibody status and its interaction with medication safety during pregnancy.

Our platform integrates the 2016 AAO screening guidelines with real-world retinal toxicity data from lupus registries. We model cumulative dose-dependent maculopathy risk using actual body weight-based dosing (5 mg/kg/day threshold), duration of use, renal function impact on drug clearance, and concurrent tamoxifen use. The AI tracks OCT screening compliance patterns and provides individualized risk projections for retinal toxicity that inform the long-term benefit-risk balance of this foundational SLE therapy.

Pediatric-onset SLE (pSLE) tends to be more severe than adult-onset disease, with higher rates of lupus nephritis and neuropsychiatric involvement. Our platform models the unique BRA challenges including growth and development impacts from long-term corticosteroid use, limited pediatric-specific efficacy data for biologics, the extended lifetime exposure to immunosuppressants, and vaccine safety considerations in immunosuppressed children. We support pediatric investigation plan frameworks that address these age-specific safety concerns.

Treatment transitions in SLE carry flare risk that must be modeled alongside medication safety. Our platform analyzes washout period safety for immunosuppressant switches, corticosteroid taper protocols and rebound flare risk, the safety of biologic-to-biologic transitions (e.g., belimumab to anifrolumab), and the impact of disease flares on cumulative organ damage scores. The AI models integrate SLEDAI and BILAG activity indices with safety event timelines to provide comprehensive transition BRA.

See ArcaScience Applied to Lupus

Request a demonstration of ArcaScience's platform configured for SLE benefit-risk analysis. Our immunology scientists will walk through multi-organ safety modeling, lupus nephritis-specific data coverage, and infection risk stratification examples.

Request SLE Briefing Explore the Platform →